Cargando…

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial

AIMS/HYPOTHESIS: The aim of this work was to study the potential long-term impact of a 7.8 years intensified, multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria in terms of gained years of life and years free from incident cardiovascular disease. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gæde, Peter, Oellgaard, Jens, Carstensen, Bendix, Rossing, Peter, Lund-Andersen, Henrik, Parving, Hans-Henrik, Pedersen, Oluf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506099/ https://www.ncbi.nlm.nih.gov/pubmed/27531506 http://dx.doi.org/10.1007/s00125-016-4065-6

Ejemplares similares

Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
por: Oellgaard, Jens, et al.
Publicado: (2018)

Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study
por: Gæde, Peter, et al.
Publicado: (2019)

A cost analysis of intensified vs conventional multifactorial therapy in individuals with type 2 diabetes: a post hoc analysis of the Steno-2 study
por: Gæde, Joachim, et al.
Publicado: (2018)

Cost-Effectiveness of Intensified Versus Conventional Multifactorial Intervention in Type 2 Diabetes: Results and projections from the Steno-2 study
por: Gæde, Peter, et al.
Publicado: (2008)

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria
por: Andersen, Sten, et al.
Publicado: (2010)

Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy
por: Broedbaek, Kasper, et al.
Publicado: (2011)

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review
por: Persson, Frederik, et al.
Publicado: (2016)

Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria
por: Reinhard, Henrik, et al.
Publicado: (2011)

Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria
por: Currie, Gemma E., et al.
Publicado: (2018)

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria
por: Zobel, Emilie H., et al.
Publicado: (2017)

NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis
por: Reinhard, Henrik, et al.
Publicado: (2011)

Marker for kidney fibrosis is associated with inflammation and deterioration of kidney function in people with type 2 diabetes and microalbuminuria
por: Poulsen, Christina Gjerlev, et al.
Publicado: (2023)

Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria
por: Winther, Signe Abitz, et al.
Publicado: (2021)

Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark
por: Safai, Narges, et al.
Publicado: (2018)

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria: A post hoc analysis of the IRMA-2 trial
por: Hellemons, Merel E., et al.
Publicado: (2011)

Steno on muscles
por: Nayler, Margaret
Publicado: (1995)

Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort
por: Ferreira, Isabel, et al.
Publicado: (2017)

Osteoprotegerin and Mortality in Type 2 Diabetic Patients
por: Reinhard, Henrik, et al.
Publicado: (2010)

Steno. Geological Papers
por: Sizer, C. A.
Publicado: (1970)

Vitamin D Levels and Mortality in Type 2 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2010)

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial
por: Lund, Søren S, et al.
Publicado: (2009)

Vitamin D Levels, Microvascular Complications, and Mortality in Type 1 Diabetes
por: Joergensen, Christel, et al.
Publicado: (2011)

Historical Symposium on Nicolaus Steno
Publicado: (1966)

Lifetime risk and years lost to type 1 and type 2 diabetes in Denmark, 1996–2016
por: Carstensen, Bendix, et al.
Publicado: (2021)

Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients
por: Reinhard, Henrik, et al.
Publicado: (2012)

Occupational Tuberculosis in Denmark through 21 Years Analysed by Nationwide Genotyping
por: Pedersen, Mathias Klok, et al.
Publicado: (2016)

Insulin Pump Treatment in Adults with Type 1 Diabetes in the Capital Region of Denmark: Design and Cohort Characteristics of the Steno Tech Survey
por: Rytter, Karen, et al.
Publicado: (2021)

Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes: An Inception Cohort Study
por: Hovind, Peter, et al.
Publicado: (2009)

Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy
por: Lajer, Maria, et al.
Publicado: (2010)

NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients
por: Reinhard, Henrik, et al.
Publicado: (2012)

Impact of Baseline Renal Function on the Efficacy and Safety of Aliskiren Added to Losartan in Patients With Type 2 Diabetes and Nephropathy
por: Persson, Frederik, et al.
Publicado: (2010)

Steno and Brain Research in the Seventeenth Century
por: Pagel, Walter
Publicado: (1970)

A Case of Occlusion of Steno’s Ducts
Publicado: (1891)

Vitamin D Levels and Asymptomatic Coronary Artery Disease in Type 2 Diabetic Patients With Elevated Urinary Albumin Excretion Rate
por: Joergensen, Christel, et al.
Publicado: (2012)

Multifactorial 10-Year Prior Diagnosis Prediction Model of Dementia
por: Dallora, Ana Luiza, et al.
Publicado: (2020)

Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus
por: Pena, Michelle J., et al.
Publicado: (2016)

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes – An observational follow-up study
por: Frimodt-Møller, Marie, et al.
Publicado: (2018)

Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3‐deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub‐study
por: Piazza, M., et al.
Publicado: (2020)

Urinary Liver-Type Fatty Acid-Binding Protein Predicts Progression to Nephropathy in Type 1 Diabetic Patients
por: Nielsen, Stine Elkjaer, et al.
Publicado: (2010)

Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes: A 12-year follow-up study
por: Nin, Johanna W., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_07jtoabcsl063v3ndq6680902o